Tesamorelin
FDA-approved GHRH analog for specific clinical indications.
Research Areas
Scientific Background
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). It has been studied for its ability to stimulate natural growth hormone production.
Areas of Investigation
Laboratory Information
Technical specifications for research settings
This compound is intended for qualified scientific research only. Not for human or veterinary use. Not for diagnostic or therapeutic applications. Researchers must comply with all applicable regulations in their jurisdiction.
Store at 2-8°C per manufacturer guidelines.
Lyophilized powder
Pharmaceutical grade
FDA-approved compound. Research use should follow appropriate protocols.
Published Literature
Extensive clinical trial data exists for Tesamorelin in its approved indication.
Regulatory Classification
Tesamorelin (Egrifta®) is FDA-approved specifically for HIV-associated lipodystrophy. All other uses are off-label and require appropriate medical oversight. This is a prescription medication.
Important Research Notice
This information is compiled from scientific literature for educational purposes only. This website does not sell, distribute, or recommend any compounds for human use. All compounds discussed are for qualified research purposes only.